🇺🇸

Index Intelligence

· daily

S&P 500 Healthcare Sector SEC Filings — April 22, 2026

Across 50 filings in the USA S&P 500 Healthcare stream, Q1 2026 earnings show robust revenue growth in select areas like med devices (Boston Scientific +11.6% YoY) and financial services adjacent to healthcare (Stifel +18% YoY, CACI +8.5% YoY), but mixed results with pressures on margins (Bankwell NIM -12bps), operating gains (Elevance -34.2% YoY), and memberships (Medicare Advantage -15.8% YoY). Healthcare-specific filings highlight positive organizational shifts at Amgen for AI-driven R&D and non-dilutive funding at TuHURA extending runway to 2028, alongside biotech events like Spruce's public offering. Over 25 13F-HR filings from managers like Pinnacle Associates, AtlasMark, and Parcion reveal extreme concentration in tech megacaps (Nvidia top in 10+ portfolios, e.g., Ketron $124M) and ETFs, with minimal healthcare exposure (e.g., Biltmore $25.6M Health Care ETF outlier), signaling institutional derisking from sector amid volatility. Capital allocation trends favor dividends (Elevance $1.72 Q2, Civista +6% to $0.18) and buybacks (News Corp $1B program), while M&A integration challenges post-deals (Pinnacle loans +118% LQ but EPS -50% YoY) dominate financials. Forward guidance largely raised (CACI rev to $9.5-9.6B, Elevance EPS $26.75+), building a catalyst calendar into Q2-Q3 2026. Portfolio-level, 7/12 earnings reporters posted YoY revenue growth averaging +20%, but 5 showed margin/NIM compression averaging -20bps, implying selective opportunities in growth outperformers.

6 high priority 44 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 21, 2026

Across 20 filings in the USA S&P 500 Technology stream (with cross-sector context), key themes include robust revenue growth in tech leaders like Intuitive Surgical (+23% YoY) and CrowdStrike (revenue +57% FY2024-2026, ARR +52%), contrasted by pressures in healthcare (Community Health Systems rev -6.1% YoY, net loss widened to $(0.43)/share). Financial institutions showed YoY strength (United Community Banks NI +18%, Community Bancorp +24%) amid NIM expansions (+29 bps for UCB) and accretive M&A, while capital returns accelerated via Adobe's $25B buyback authorization (through 2030), Mueller's 40% dividend hike and $75M repurchases, and UCB's share buybacks. Period-over-period trends reveal 7/12 reporting companies with double-digit YoY revenue gains averaging +20%, but QoQ softness in banks and operating cash declines (Mueller -30%). Insider alignment positive via CrowdStrike's 100K PSU award to President (tied to 3-year TSR vs S&P 500, up to 200% payout), no notable selling. Forward-looking catalysts include UCB-Peach State merger ($0.09 EPS accretion 2027), CRWD's $20B ARR ambition by 2028, and multiple AGMs/proxies in June. Portfolio implication: overweight growth tech with buyback support, monitor bank M&A regulatory risks.

7 high priority 13 medium 20 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 21, 2026

Across 26 NASDAQ-100 related filings dated April 21, 2026, regional banks like United Community Banks (UCB) and Community Bancorp showcased robust Q1 results with net income up 18-24% YoY, NIM expansion (+29 bps YoY for UCB), and loan/deposit growth, alongside M&A activity including UCB's $100M Peach State acquisition at 1.9x TBV expecting $0.09 EPS accretion in 2027. Tech and industrials leaders reported strong growth: Intuitive Surgical revenue +23% YoY on 17% procedure growth, Mueller Industries sales +19% YoY amid copper price surge, and Adobe authorized $25B buyback through 2030. Healthcare showed divergence with Community Health Systems revenues down 6.1% YoY and Adjusted EBITDA -18% due to divestitures, contrasting positive operational metrics elsewhere. Capital allocation trends favor shareholders with repurchases (UCB 1.09M shares, Mueller 650k shares, Adobe $25B program) and dividend hikes (Mueller +40% to $0.35, Community Bancorp $0.25). Mixed sentiments prevail in speculative names like Faraday Future (financing but 45% share increase sought) and Broadcom (AGM dissent on comp/director). Portfolio-level, 5/7 financials exhibited YoY net income growth averaging +20%, signaling sector resilience, while forward catalysts cluster around June AGMs and merger approvals.

8 high priority 18 medium 26 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 21, 2026

Across 50 filings from S&P 500 Financials and related streams, dominant themes include robust institutional portfolio tilts toward tech megacaps (Apple, MSFT, NVDA appearing in 20+ 13F-HR filings) and ETFs, signaling conviction in growth amid volatility; strong capital allocation in financial services with Synchrony Financial launching $6.5B buyback and 13% dividend hike, UnitedHealth targeting $2B repurchases by Q2-end, and News Corp's $1B program. Period-over-period trends show mixed resilience: Synchrony Q1 net earnings +6% YoY to $805M with NCOs -96bps to 5.42%, UnitedHealth revenues +2% YoY but Optum dip QoQ, First United NI +16% YoY to $6.7M and NIM + to 3.83%, though loans flat/declining in banks. SPAC activity surges with $1.2B Forge Nano merger, $303M Key Mining deal, and multiple IPO filings, highlighting M&A catalysts. Forward-looking positives include UnitedHealth's FY2026 EPS guidance >$18.25 (raised), Synchrony's monthly stats continuity, and accretive deals like Onto Innovation's $710M Rigaku stake. Overall, financials exhibit margin stability and shareholder returns amid flat lending, but SPACs and 13Fs point to broader equity optimism; risks cluster in covenant waivers (Inotiv) and prelim losses (Allbirds). Portfolio-level: 30+ 13Fs aggregate $10T+ AUM with 40%+ tech/ETF exposure, avg unchanged QoQ.

15 high priority 35 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 21, 2026

Across 50 SEC filings from diverse sectors (despite Consumer Staples focus, dominated by industrials, financials, REITs, and biotechs), Q1 2026 results show robust revenue growth averaging +15-25% YoY in reporting companies like GE Aerospace (+25%), Zurn Elkay (+11%), and Valmont (+6%), but margin compression in 4/7 key earners (e.g., GE -490 bps GAAP, Aerospace -230 bps). Capital allocation remains shareholder-friendly with dividends (Delek $0.255/share, Armour $0.24/share, Valmont +13% to $0.77) and buybacks (Zurn $50M, Donnelley $150M new program, Valmont $57.5M Q1). Positive M&A/licensing (NEXGEL triples revenue pro-forma to $35M) and financings (Prelude $90M raise) offset risks like operational disruptions (Aspen explosion) and partnership terminations (Rigel with Lilly). Forward guidance largely maintained or raised (GE full-year EPS $7.10-$7.40, Valmont $21.50-$23.50, Zurn Q2 8-9% growth), signaling resilience; institutional 13Fs (e.g., Pinnacle, Morton Brown) show heavy tech/ETF tilts with no major shifts. Proxy-heavy filings highlight governance refreshes and compensation approvals, with mixed sentiment (25% positive, 30% mixed, 45% neutral). Portfolio-level: 6/10 key filers grew EPS YoY, but 3 saw loan/asset declines; watch Q1 earnings catalysts Apr 22-25 for guidance updates amid tariff risks.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 21, 2026

Across 50 filings in the USA S&P 500 Industrials stream (April 21, 2026), dominant themes include robust revenue growth in defense and aerospace (e.g., GE +25% YoY, RTX +9% YoY organic, Northrop +4% YoY) offset by margin compression (GE profit margin -490 bps, RTX segment mix issues), mixed bank earnings irrelevant to core industrials but showing NIM expansion (Peoples 4.16%, United 3.65% +29 bps YoY), and heightened SPAC/M&A activity in adjacent tech/housing (Boxabl merger, Forge Nano $1.2B deal). Period-over-period trends reveal 7/10 key industrials with YoY revenue growth averaging +15% but operating margins down avg -150 bps due to costs/tariffs; capital returns strong with buybacks (Tractor Supply $118M) and dividends (Delek $0.255/share). Forward guidance largely reaffirmed or raised (RTX EPS to $6.70-6.90, Danaher to $8.35-8.55), signaling conviction amid sector rotation. 13F filings (20+) show heavy industrials exposure (e.g., Caterpillar top in Independent Wealth $18.5M, Generali Freeport-McMoRan $52M), indicating institutional accumulation. SPAC resurgences in quantum/housing flag construction/aerospace adjacency opportunities, while pharma filings (Tarsier IPO, Genprex trials) suggest biotech crossover. Overall, bullish on defense backlog growth ($95B Northrop) but cautious on industrial cost pressures; actionable now: overweight RTX/GE pre-guidance catalysts.

12 high priority 38 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 21, 2026

Across the 8 filings in the USA S&P 500 Energy intelligence stream, core Energy players like Halliburton and Devon Energy show mixed performance: Halliburton doubled Q1 2026 net income YoY to $461M despite flat $5.4B revenue and segment declines, while Devon exceeded 2025 FCF ($2.56B vs $2.5B target) and production targets (840 MBOE/d vs 823) but posted -13% YoY FCF decline amid a pending Coterra merger. Institutional 13F filings from Williams & Novak and Stokes Capital reveal neutral, diversified portfolios heavy in ETFs with minimal Energy exposure. Non-Energy filings highlight growth in Interactive Brokers (17% YoY revenue to $1.67B), a SPAC IPO by Hall Chadwick aiming for $265M raise, positive board addition at Howard Hughes, and neutral severance tweaks at Robert Half. Overarching themes include resilient profitability in Energy services amid flat revenues, M&A catalysts like Devon's Feb 1, 2026 Coterra deal, steady capital returns (Halliburton $100M buybacks + $142M dividends), and neutral institutional conviction. Portfolio-level trends show international offset for North America weakness in Energy (Halliburton Int'l +3% vs NA -4%), signaling sector rotation opportunities. Critical implications: Monitor Energy M&A and Q2 catalysts for alpha amid geopolitical drags.

3 high priority 5 medium 8 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 21, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream on April 21, 2026, dominant themes include heavy institutional accumulation in mega-cap tech stocks (Apple, Microsoft, NVIDIA, Alphabet) via 13F-HR disclosures from 16 managers totaling billions in AUM, signaling sustained conviction amid market rotations. Banking sector shows resilient YoY growth (e.g., United Community Banks +18% net income YoY, +12% revenue) but QoQ softness in income and rising provisions, with NIM expansions averaging +20 bps YoY. Healthcare mixed with UnitedHealth raising FY2026 adjusted EPS guidance to >$18.25 despite Optum dip, while tech/industrials highlight positive capital returns (AppLovin $2.2B buybacks, Delek dividend) and M&A (Onto Innovation $710M stake). SPAC IPO filings (AEI CapForce, Vernal, Collective, East West) indicate renewed blank-check activity with dilution risks and 18-24 month de-SPAC deadlines. Proxy statements cluster around June 2026 annual meetings, building a catalyst calendar. No widespread insider selling; instead, performance awards to execs (CrowdStrike, PPG) reflect alignment. Portfolio-level trends: 4/5 banks report YoY EPS growth averaging +15%, but 3 show QoQ net income declines; overall sentiment leans neutral-positive with mixed in financials.

17 high priority 33 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 21, 2026

Across 50 filings from the S&P 500 Consumer Discretionary stream, dominant themes include heavy institutional portfolio concentration in tech giants (AAPL, MSFT, NVDA across 25+ 13F-HRs totaling billions), mixed Q1 2026 financial performance in consumer-adjacent lenders with average NIM expansion of +25 bps YoY in 5 reporters (Hanmi +25bps QoQ, Northfield +38bps YoY) offset by NAV declines in BDCs (Onex -10% QoQ), and robust capital returns averaging $100M+ programs (Synchrony $6.5B buyback, Donnelley $150M). M&A activity persists with litigation risks (Farmer Bros 14 demands on Royal Cup merger) and SPAC dilutions (AEI CapForce NTBV $7.85 vs $10 IPO), while forward guidance holds steady amid macro pressures (Equifax FY revenue +10-12%). Portfolio-level trends show deposit growth in banks (+1.8% QoQ Hanmi, +8.4% ann. Northfield) but loan declines (-0.3% Hanmi, -5.1% ann. Northfield), signaling cautious lending. Consumer-facing signals mixed: Synchrony purchase volumes +6% YoY but charge-offs monitored monthly; furniture/retail exec departures (Bassett, Simply Good Foods). Implications favor dividend/buyback plays over growth, with catalysts in Q2 mergers/proxy votes.

8 high priority 42 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 21, 2026

Across 50 filings in the USA S&P 500 Healthcare intelligence stream (with heavy financial services crossover), Q1 2026 results for reporting companies show average revenue growth of ~8% YoY (range 2-23%, e.g., UNH +2%, ISRG +23%, Danaher +3.7%, MSCI +14%), mixed margins (expansions in UHC +40bps, NIM Hanmi 3.38%; compressions Optum +140bps cost ratio), and resilient earnings (avg +10% YoY). Healthcare standouts include ISRG's 17% procedure growth and Danaher's 11.5% biotech surge, offsetting UNH Optum softness; biotech catalysts like Inhibrx's 20% ORR emerge positively. Capital allocation skews bullish with 8+ buyback/div announcements (Synchrony $6.5B no expiry, UNH $2B Q2, Danaher no Q1 buys vs $1.1B prior). 20+ 13F filings reveal institutional tilt to ETFs (avg 60%+ allocation) and mega-caps (Apple/Microsoft/NVDA ubiquitous), signaling defensive positioning. Guidance mostly raised (UNH FY EPS >$18.25, Danaher $8.35-8.55), but Prudential's sales suspension extension flags Japan risks. Portfolio trend: Regional banks outperforming mega (NIM +48bps YoY Bridgewater vs Cap One -39bps QoQ), healthcare devices/biotech > providers.

6 high priority 44 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 20, 2026

The April 20, 2026, filings for the USA S&P 500 Technology stream reveal a heavy focus on governance with 7 proxy-related filings (DEF 14A/DEFA14A), signaling peak proxy season for annual meetings, alongside pivotal tech leadership shifts and portfolio signals. Key highlights include Apple's CEO transition from Tim Cook to John Ternus on September 1, 2026 (materiality 10/10), and Synopsys' strong AGM approval for equity plans and compensation (mixed sentiment, materiality 6/10). Limited period-over-period financial data shows outlier strength in non-core Muncy Columbia (+64.6% YoY net income, +18.6% net interest income), while Trust Co of Oklahoma's 13F underscores institutional conviction in tech via $41.6M VGT, $17.2M AAPL, and $9.4M MSFT holdings. No broad margin compression or revenue trends emerge across tech pure-plays, but forward-looking catalysts cluster around June AGMs and Apple's Q3 leadership change. Portfolio-level patterns indicate neutral-to-mixed sentiment (9/13 neutral/mixed), with capital allocation light except Muncy's $1.00 special dividend payable April 23, 2026. Implications favor monitoring tech leadership stability and governance votes for conviction signals amid sparse operational metrics.

7 high priority 6 medium 13 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 20, 2026

Across 15 filings from the USA NASDAQ-100 stream (April 20, 2026), proxy statements dominate (9/15 filings), signaling peak governance season with annual meetings clustered in late May to mid-June 2026, focusing on director elections, auditor ratifications, and equity plan expansions. Notable outliers include Muncy Columbia Financial's stellar Q1 2026 results with net income surging 64.6% YoY to $7.2M, NIM expanding 50bps YoY to 4.33%, and deposit growth of $40.8M QoQ, contrasting neutral sentiment elsewhere. Financing activities highlight risks, such as Faraday Future's $45M dilutive notes (9% and 3.5% interest, convertible after 6 months subject to Nasdaq $0.0603 min price), while Acadia Realty's amended credit facility garners positive sentiment. Apple's planned CEO transition (Tim Cook to Exec Chair, John Ternus to CEO on Sept 1, 2026) is neutral but material, with comp details pending. Limited period-over-period data shows Muncy as a strong financial performer amid sparse metrics; forward-looking includes AITX FY2027 revenue targets and multiple proxy catalysts. Portfolio-level: Neutral sentiment prevails (13/15), with governance focus outweighing operational trends, but capital raises signal cash needs in EVs/biotech.

7 high priority 8 medium 15 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 20, 2026

Across 50 SEC filings from S&P 500 Financials and adjacent sectors on April 20, 2026, dominant themes include a surge in M&A activity (e.g., QXO-TopBuild $17B, USA Rare Earth-Serra Verde $2.8B, Calavo-Mission Produce), mixed Q1 2026 financial results with banks like Investar (+113% QoQ net income, +41% loans) and SmartFinancial (NIM +10bps QoQ) showing resilience amid NIM expansion, contrasted by AUM declines at Principal Financial (-1.2% QoQ impact) and widening losses elsewhere (Blue Chip cash to $0). Period-over-period trends reveal revenue growth in 4/10 reporting firms (e.g., Cleveland-Cliffs +6% YoY, Tuniu +12.5% YoY) but frequent margin pressures and rising NPLs (Investar +118% QoQ). Proxy season ramps up with 8+ annual meetings in May-June 2026, SPAC extensions signal liquidation risks, and capital allocation leans toward buybacks (News Corp $1B program). Portfolio-level, M&A catalysts cluster in Q3 2026 closings, offering alpha in targets/premiums, while banking outliers beat sector NIM trends (+20-39bps QoQ vs implied flat peers). Overall, actionable intelligence favors M&A arbitrage and select bank longs amid sector rotation.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 20, 2026

Across 50 filings in the USA S&P 500 Consumer Staples intelligence stream (though spanning broader sectors like materials, biotech, SPACs, and financials), key themes include modest revenue growth (avg +4% YoY in reporting firms like Cleveland-Cliffs +6%, Flexsteel +1%, Jayud +6.3%) paired with significant loss narrowing (Cleveland EBITDA +$274M YoY improvement, Elong -82% net loss YoY, Jayud op loss -28% YoY), signaling operational resilience amid macro pressures. M&A and SPAC activity surges with 5+ deals (e.g., Piermont-Tigerless $280M EV H2 2026 close, Constellation-Calpine completed Jan 2026, Limoneira $16M asset sale w/$9.3M impairment). Proxy filings dominate (20+ DEF/DEFA14A) for May-June AGMs, reflecting governance focus but limited financial insights; 13Fs show neutral institutional positioning in ETFs/tech giants. Consumer Staples exposure thin (Smithfield neutral proxies), but outliers like Nisun's -99% YoY rev collapse highlight vulnerability. Forward catalysts cluster: earnings May 11 (FutureFuel), SPAC votes May 1 (ClimateRock), signaling near-term volatility. Portfolio implication: favor improving profitability plays, monitor SPAC de-SPAC risks for alpha.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 20, 2026

The 50 filings for USA S&P 500 Industrials stream (April 20, 2026) are dominated by 25+ 13F-HR disclosures from investment managers revealing persistent overweight to mega-cap tech (e.g., Apple, Nvidia, MSFT topping 80% of portfolios, with total values exceeding $1T across filers), alongside selective QoQ trims like -45% Apple shares by Inscription Capital. Limited pure Industrials action highlights Stanley Black & Decker's affirmation of FY2026 guidance unaffected by Section 232 tariff changes (positive resilience signal). Small-cap financing pressures emerge via massive dilutions (AURI 841M shares at 75% discount exhausting authorized shares), new dilutive debt (Faraday Future $45M notes), and Nasdaq compliance extensions (Generation Income to Aug 2026). Energy metrics deteriorate at San Juan Basin Royalty Trust (gas volumes -10.1% MoM to 1.89MMcf, prices -8.8% MoM to $2.70/Mcf, excess costs +$445k gross MoM, no April distribution). Proxy season ramps with 8+ DEF/DEFA14A filings (e.g., ACIW June 2 meeting), while non-core biotechs show clinical catalysts (Prelude IND mid-2026). No broad sector PoP revenue/margin trends due to filing mix, but capital allocation leans toward equity incentives (BBSI +1.2M shares or 4.9% OS) and securitizations (Bridgecrest ABS yields 3.97-5.19%). Implications: Tech rotation risk overshadows quiet Industrials stability; monitor dilutions and compliance for volatility.

10 high priority 40 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 20, 2026

Across the four filings in the USA S&P 500 Energy intelligence stream, neutral sentiment prevails with average materiality of 4.25/10, reflecting routine operational, governance, and holdings disclosures rather than major financial shifts. No significant period-over-period comparisons available, but Neogen's completion of operational qualifications for Petrifilm SKUs signals manufacturing progress amid validation efforts, potentially boosting capacity YoY. IIOT-OXYS expanded Series D Convertible Preferred Stock authorization to 500 shares (from unspecified prior, with 210 outstanding at $1,200 stated value), enhancing capital flexibility via board authority for up to 10M preferred shares without shareholder vote. BRT Apartments Corp. demonstrates robust governance with 100% compliance to stock ownership guidelines (CEO 4x salary, directors 3x retainer) and high meeting attendance (≥75% for board/committees), though 64% AGM turnout. Friedenthal Financial's 13F reveals a stable $199.5M portfolio (244 positions, 100% sole discretionary), heavily tilted to ETFs (top: iShares Core S&P Total U.S. at $21.9M/11%). Absent insider trading patterns, guidance changes, or capital allocation shifts, the sector shows stability with no portfolio-level growth/margin trends; implications include low near-term volatility but opportunities in Neogen's investor tours for operational insights.

1 high priority 3 medium 4 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 20, 2026

Across 50 SEC filings from the USA Dow Jones 30 intelligence stream (April 20, 2026), institutional 13F-HR disclosures dominate (over 70%), revealing overwhelming conviction in mega-cap tech with Apple, Nvidia, Alphabet, and Microsoft comprising top holdings in 25+ portfolios totaling billions, signaling sustained bullish momentum in Big Tech despite no QoQ changes. Banking sector shows resilient Q1 2026 earnings with ServisFirst Bancshares NI +31.2% YoY (EPS +31%) and NIM +61 bps YoY, Investar Holding NI +113% QoQ post-acquisition, though marred by rising NPAs (ServisFirst 1.00% vs 0.40% YoY). M&A catalysts advance with Calavo Growers HSR clearance for Mission Produce merger (expected Q ending July 31, 2026) and Piermont Valley SPAC deal valuing Tigerless Health at $280M (H2 2026 close). Steel recovery mixed at Cleveland-Cliffs with rev +6% YoY but $229M net loss; energy trusts falter (San Juan Basin no April distribution amid costs > rev by $5M). High materiality risks from bankruptcies/delisting (QVC Group 10/10, Charles & Colvard 10/10) highlight consumer distress, while biotech/fintech fundraising (Enveric $5-13.9M, Faraday $45M notes) adds dilutive pressures. Portfolio-level trends: NIM expansion in 2/3 banks (avg +50 bps), but credit deterioration (NPAs up); tech holdings stable across RIAs averaging 30-50% allocation.

14 high priority 36 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 20, 2026

Across 50 filings dominated by regional bank Q1 2026 earnings and proxy statements, key themes include resilient loan and deposit growth (avg +5-8% annualized QoQ across 6 banks) offsetting NIM compression (-5-10 bps QoQ in 4/6 cases) and mixed profitability (3/6 banks hit record NI). Consumer Discretionary touches like Cleveland-Cliffs (steel/auto) show revenue acceleration (+6% YoY, +14% QoQ) with improved EBITDA but weather-impacted losses, while Aptiv and American Axle highlight strong governance ahead of AGMs. Institutional 13F-HR filings (12 instances) reveal persistent mega-cap tech bias (AAPL, AMZN, GOOG top holdings in 10/12), signaling defensive positioning. M&A activity (e.g., Columbia/Northfield merger, Brookfield Oaktree acquisition) and debt amendments (e.g., Fortress extension to 2028) indicate active capital markets, but derivative losses (Infinity $65M) and covenant waivers (FMC leverage) flag vulnerabilities. Forward-looking stability in Cleveland-Cliffs FY shipments (16.5-17M tons) and multiple AGMs in May-June 2026 build a catalyst-rich calendar. Overall, mixed sentiment (12/50) underscores banking strength amid macro pressures, with actionable alpha in outperforming lenders and governance plays.

13 high priority 37 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 20, 2026

The 50 filings, despite the Healthcare stream focus, predominantly feature regional banks' Q1 2026 earnings with YoY net income growth averaging +35% across 7 reporters (e.g., Wintrust +2% QoQ record, Zions +38% EPS YoY, Columbia +47% YoY), offset by QoQ softness in NIM (e.g., Zions -4bps, BOK -8bps) and deposits in some, alongside improving credit quality (charge-offs down in 5/7). Institutional 13Fs (15 filings) reveal persistent overweight in tech mega-caps (Apple, MSFT, NVDA, AMZN top in 12/15, Eli Lilly prominent in Tower View $8.9M and Lilly Endowment $84.5B stake) and ETFs, signaling defensive equity/bond tilts amid volatility. Biotech highlights include positive capital raises (Enveric $5M upfront +$8.9M potential, Dare $100K Reg A closing) contrasting DAQO's -35% FY2025 revenue decline. Proxy/AGM cluster (20+ filings) peaks May-June 2026 with director elections and auditor ratifications, mostly neutral. Mixed sentiment dominates (12/50), with banking resilience and tech conviction as key themes implying sector rotation opportunities into financials post-Q1 strength.

13 high priority 37 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 17, 2026

The 20 filings reveal a bifurcated S&P 500 Technology landscape: robust institutional conviction in mega-cap tech leaders (Broadcom, Apple, Nvidia topping multiple 13Fs with $3.7B+ positions) contrasts sharply with distress in micro/small-cap tech/biotech adjacents (MBIO delisting risk, Madison Tech zero revenues/losses +6.4% YoY, Acquisition Corp cash to $85). Key period trends include Tencent Music's strong consolidated revenue +15.9% YoY to RMB32.9B and profit +59.7% YoY, offset by VIE gross profit -55.5% YoY; Chemung Financial Q1 NI +53.3% YoY (tech holdings heavy); mixed SPAC swings to losses. Critical developments: MAIR IPO at $27/share (82M shares, trading Apr 16), Cumulus $600M debt cut via bankruptcy approval, C2 Blockchain insider cancels 245M shares, TI strong AGM votes (board 100% elected). Capital allocation leans conservative (Chemung $0.34 div, Evommune no divs planned); no major insider buys/sells beyond C2 reduction. Portfolio implications: overweight large-cap semis/AI (13Fs aggregate billions in AVGO/NVDA/AAPL), avoid microcaps, monitor IPOs/restructures for alpha.

7 high priority 13 medium 20 total filings